mercredi 30 août 2017

Onco Actu du 30 août 2017

1. Biologie

Bowel cancer study reveals impact of mutations on protein networks [Sanger Institute]

3.1 Tabac

Leading Health Groups Demand Film Industry Give R-Rating to Movies that Depict Smoking [ACS]

3.1.1 Tabac - e-cigs

Fears over e-cigarettes leading to smoking for young people unfounded – study [The Guardian]

3.3 Prévention - Vaccins

HPV vaccination rates ticking upward, CDC says as it urges more uptake [FiercePharma]

Adolescent and Young Adult Cancer Survivors Are Less Likely to Have HPV-Vaccination than Peers [ESMO]

3.8 Prévention - Alimentation

Huge new study casts doubt on conventional wisdom about fat and carbs [STAT]

Life-saving fruit and vegetable diet need only be three portions – study [The Guardian]

4.12 Biopsies liquides

Detecting early signs of cancer in the blood [NIH]

5.12.1 Immunothérapies - partenariats

Five Prime cuts loose from InhibRx immuno-oncology deal [FierceBiotech]

5.12.5 Immunothérapies - Pharma

Celgene, Google double down on Armo’s PhIII immuno-oncology drug with $67M round [EndPoints]

5.12.8 Immunothérapies - Economie

How will Gilead price CAR-T? With Kite buy, the top biotech joins Novartis in spotlight [FiercePharma]

Gilead’s $11.9 billion purchase of a groundbreaking cancer therapy could drag it into a new debate on prices [Washington Post]

Novartis CEO opens door to cancer patient demanding ‘fair’ CAR-T pricing [FiercePharma]

5.2 Pharma

U.S. FDA and European Medicines Agency Accept Regulatory Submissions for BOSULIF® (bosutinib) for the Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia [Pfizer]

5.2.1 Pharma - Partenariats

Jazz Pharma, ImmunoGen Strike Up Drug Pact in Leukemia and More [Xconomy]

Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors [Genmab]

Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort [EndPoints]

5.2.2 Pharma - Fusions & Acquisitions

For Gilead Kite is no Pharmasset [EP Vantage]

5.3 Traitements - FDA, EMA, NICE...

FDA targets rogue clinic using Sanofi's smallpox vaccine in unapproved cancer therapy [FiercePharma]

Adverse Events: A Look Under the Hood [In the Pipeline]

Making Sense of FAERS: Researchers Suggest Fixes to FDA's Adverse Event Database [RAPS]

5.6 ESMO

New Phase 3 Data for Abemaciclib and Ramucirumab Presented at ESMO 2017 Congress [Lilly]

6. Lutte contre les cancers

NIH’s All of Us Research Program expands national network of medical centers [NIH]

Insights in Oncology: Burnout and the Specialty of Oncology [Clinical Oncology News]

Cancer patients lack access to fertility support [Reuters]

6.1 Observation

Why a growing number of women with breast cancer are choosing double mastectomy [STAT]

6.10 Politiques

UK report plans boost for life sciences as Brexit looms [Reuters]

6.11 Patients

As cancer progresses some patients weep, some get angry and others are bewildered [The GUardian]

6.5 Médecines alternatives

Cancer is ‘natural.’ The best treatments for it aren’t [STAT]

6.6 Publications

Carlo Croce, OSU cancer researcher under investigation, retracts paper [Retraction Watch]

Medical Journals Have a Fake News Problem [Bloomberg]